Open Forum Infectious Diseases (ISSN: 2328-8957; E-ISSN: 2328-8957) is a leading open-access journal published by Oxford University Press, dedicated to advancing the field of infectious diseases. Since its inception in 2014, the journal has provided a platform for researchers to disseminate impactful findings in a rapidly evolving domain, achieving a remarkable Q1 ranking in both the Infectious Diseases and Oncology categories as of 2023. The journal encourages rigorous and innovative research, contributing significantly to global health discussions and informing best practices in clinical settings. As an open-access journal, it ensures that its content is accessible to a wide audience, fostering collaboration and knowledge sharing among researchers, professionals, and students alike. Positioned in the heart of the United States, Open Forum Infectious Diseases serves as a critical resource for the academic community, and its continued commitment to quality and relevance secures its status as an essential publication in the field.

MICROBIAL PATHOGENESIS, published by Academic Press Ltd - Elsevier Science Ltd, is a prominent journal in the fields of Infectious Diseases and Microbiology, with a notable impact factor and classified in the Q2 quartile for both categories as of 2023. Since its inception in 1986, this journal has provided a platform for the dissemination of cutting-edge research that enhances our understanding of microbial infections and their implications in health and disease. The journal is indexed in Scopus, ranking #80 among 344 in Infectious Diseases and #57 among 182 in Microbiology, underscoring its significant contribution to the scientific community. Although it operates under a traditional subscription model, the content is vital for researchers, professionals, and students focused on the dynamics of microbial pathogenesis and the development of innovative therapeutic strategies. The journal's comprehensive scope aims to foster advancements in this critical area of study, bridging the gap between laboratory research and clinical applications.

Tuberculosis is an esteemed peer-reviewed journal specializing in the fields of Infectious Diseases, Immunology, and Microbiology, published by Churchill Livingstone since 1974. With a scope aimed at advancing the understanding and management of tuberculosis and related infectious diseases, the journal provides a platform for innovative research findings, clinical practices, and policy discussions. It is ranked in the Q2 category for both Infectious Diseases and Microbiology (medical), reflecting its significance in the academic community and the impact of its published work. The journal's commitment to openness is evident in its access options, fostering wider dissemination of knowledge. With an impact factor that underscores its relevance, Tuberculosis serves as a crucial resource for researchers, healthcare professionals, and students dedicated to combatting these pressing health challenges. The journal operates from its production headquarters in Edinburgh, Scotland, ensuring a strong connection to the international research community.

JOURNAL DE MYCOLOGIE MEDICALE is a premier publication in the field of infectious diseases, particularly focusing on the study of mycology and its clinical implications. Published by MASSON EDITEUR, this esteemed journal is based in France and has been disseminating valuable research since its inception in 1994. With an ISSN of 1156-5233 and an E-ISSN of 1773-0449, it plays a critical role in advancing knowledge in mycological infections, positioning itself in the Q3 category for infectious diseases as per the 2023 quartiles. As indicated by its ranking in Scopus, ranking #142 out of 344 in the medicine-infectious diseases category, the journal maintains a prominent presence within the academic community, appealing to researchers, healthcare professionals, and students alike. Although access options are not open access, the journal endeavors to promote a deeper understanding of mycological studies that are crucial for combating ongoing and emerging infectious threats. As it continues to converge on new findings up to 2024, JOURNAL DE MYCOLOGIE MEDICALE remains an essential resource for those invested in the critical intersections of mycology and medicine.

Emerging Microbes & Infections is a premier open access journal, published by Taylor & Francis Ltd since 2012, dedicated to advancing the understanding of microbial infections and their implications in human health. With an impressive Q1 ranking across multiple categories—including Drug Discovery, Epidemiology, Immunology, and Infectious Diseases—this journal is at the forefront of research in the microbiological sciences. Covering a diverse range of topics, it serves as a vital resource for researchers, healthcare professionals, and students alike. The journal's commitment to open access ensures worldwide dissemination of cutting-edge findings, fostering collaboration and innovation in tackling challenges posed by emerging infections. As part of the thriving academic community in the United Kingdom, Emerging Microbes & Infections plays a crucial role in shaping the future of infectious disease research and public health.

ACTA VIROLOGICA, a key journal in the field of virology and infectious diseases, is published by FRONTIERS MEDIA SA in Slovakia, serving the global scientific community with groundbreaking research since its inception in 1957. This esteemed journal, identified by ISSN 0001-723X and E-ISSN 1336-2305, provides a platform for rigorous peer-reviewed articles that contribute significantly to our understanding of viral pathogens and their implications in medicine. Positioned within the Q3 category for both Infectious Diseases and Miscellaneous Medicine, and a Q4 category for Virology in 2023, ACTA VIROLOGICA offers crucial insights into the evolving landscape of virology research. With its robust accessibility options, this journal appeals to a diverse readership, including researchers, healthcare professionals, and students, fostering a collaborative environment to advance the field of virology. The editorial objective is to enhance the catalog of knowledge pertaining to viruses, promoting innovative approaches in prevention, diagnostics, and treatment. Located at AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE CH-1015, SWITZERLAND, ACTA VIROLOGICA continues to be a vital resource in the collective efforts to combat viral disease challenges.

Korean Journal of Parasitology is a respected publication in the field of parasitology, originating from the esteemed Korean Society of Parasitology and affiliated with Seoul National University College of Medicine. Established in 1977, this journal focuses on disseminating significant research findings related to parasitic diseases, their vectors, and control measures, serving as a vital resource for researchers, medical professionals, and students alike. Although coverage in Scopus has been discontinued as of 2022, the journal remains a valuable platform for in-depth studies within the areas of Infectious Diseases and Immunology. With an ISSN of 0023-4001 and an E-ISSN of 1738-0006, the journal promotes open access to enhance academic sharing. Despite its current Scopus rankings, which place it in the 38th percentile for Infectious Diseases and 37th percentile for Immunology and Microbiology (Parasitology), it continues to contribute to the global discourse on parasitological research, encouraging collaboration and emphasizing the importance of this field in public health.

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases is a leading peer-reviewed journal dedicated to advancing the field of infectious diseases, particularly focusing on tuberculosis and other mycobacterial infections. Published by ELSEVIER in the United Kingdom with an impressive open access model since 2015, this journal aims to provide a platform for the dissemination of high-quality research, clinical findings, and innovative methodologies in the management of mycobacterial diseases. With a commendable impact, the journal currently holds a Q2 ranking in multiple categories including Infectious Diseases and Pulmonary and Respiratory Medicine, reflecting its influence in the academic community. The journal is dedicated to serving researchers, healthcare professionals, and students by offering access to essential information that can improve patient outcomes and enhance public health strategies. As the field of mycobacterial diseases continues to evolve, Journal of Clinical Tuberculosis and Other Mycobacterial Diseases remains a crucial resource for those seeking to remain at the forefront of research and clinical practice.

The Journal of Clinical Virology Plus, published by Elsevier, is an essential resource for researchers and professionals in the fields of virology and infectious diseases. Launched in 2021, this journal aims to bridge the gap between clinical research and application, fostering a deeper understanding of viral pathogenesis, diagnostics, and therapeutic strategies. With an ISSN of 2667-0380, this open-access journal brings cutting-edge findings to the global scientific community, facilitating the rapid dissemination of knowledge critical for advancing public health. Positioned in the Q3 category for both Infectious Diseases and Virology in 2023, its ranking reflects its growing influence and relevance in the academic landscape. The journal strives to support innovative research, collaborative studies, and comprehensive reviews that address contemporary challenges in clinical virology. As it converges through the years from 2021 to 2024, Journal of Clinical Virology Plus aims to be a central hub for vital discussions and breakthroughs in this dynamic field.

MEDICAL MYCOLOGY, published by Oxford University Press, is a premier journal dedicated to the study of fungal infections and their clinical implications. With an ISSN of 1369-3786 and an E-ISSN of 1460-2709, this journal has established itself as a vital resource in the fields of Infectious Diseases and Medicine, holding a respectable Q2 ranking for both categories and a Q1 ranking in the veterinary sector in 2023. Spanning a rich history from 1962 to 2024, MEDICAL MYCOLOGY serves as a platform for innovative research, case reports, and review articles that contribute to the understanding and management of mycological diseases. The journal's commitment to advancing knowledge is reflected in its Scopus rank of #120 out of 344 in Medicine - Infectious Diseases, positioning it within the 65th percentile. With open access options available, it aims to ensure that critical research is accessible to a global audience, enhancing collaboration and knowledge sharing among researchers, healthcare professionals, and students alike.